BC
EWTX icon

Bridgefront Capital’s Edgewise Therapeutics EWTX Stock Holding History

Bridgefront Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$373K Sell
9,184
-2,625
-22% -$90.5K 0.1% 328
2026
Q1 		$372K Buy
+11,809
New +$341K 0.09% 333

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgefront Capital's EWTX Position: Q2 2026 in Review

Bridgefront Capital reduced its Edgewise Therapeutics (EWTX) stake by 22% in Q2 2026, selling an estimated $90.5K and leaving 9,184 shares worth $373K. The position accounts for 0.1% of the portfolio, ranked #328.

Bridgefront Capital first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Bridgefront Capital held 9,184 shares of Edgewise Therapeutics worth $373K as of Q2 2026.
  • Bridgefront Capital sold 2,625 Edgewise Therapeutics shares in Q2 2026, an estimated $90.5K.
  • Edgewise Therapeutics made up 0.1% of Bridgefront Capital's portfolio in Q2 2026, its #328 holding.
  • Bridgefront Capital first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.